Table 1 Comparison of demographic and clinical features between PD and PSP patients.
Feature | PD | PSP | p-value | Newly diagnosed PD | Early PSP | p-value |
|---|---|---|---|---|---|---|
Age | 63.27 ± 8.54 | 67.81 ± 7.48 | 0.027* | 63.33 ± 8.74 | 63.50 ± 5.96 | 0.845 |
Gender (M/F) | 55/28 | 11/10 | 0.238 | 17/10 | 7/5 | 0.784 |
Disease duration (years) | 3.46 ± 3.20 | 2.52 ± 1.17 | 0.496 | < 1 | 1.75 ± 0.43 | NA |
Levodopa Equivalent Daily dose (mg) | 377.18 ± 39 6.70 | 409.44 ± 258.9 | 0.411 | 0.00 ± 0.00 | 319.00 ± 177 80 | NA |
Body Mass Index | 27.17 ± 3.38 | 28.33 ± 4.68 | 0.265 | 26.18 ± 3.06 | 26.73 ± 4.61 | 0.849 |
Hoehn & Yahr | 1.69 ± 0.47 | 2.32 ± 0.50 | < 0.001* | 1.42 ± 0.50 | 2.22 ± 0.47 | 0.001* |
MDS-UPDRS: part III | 19.46 ± 8.99 | - | NA | 12.85 ± 6.17 | – | NA |
PSP-RS V | – | 5.81 ± 2.73 | NA | – | 5,.3 ± 2.87 | NA |
PSP-RS VI | – | 7.28 ± 4.55 | NA | – | 6.58 ± 3.73 | NA |
Mini-mental state examination | 26.87 ± 2.31 | 25.16 ± 3.06 | 0.003* | 26.92 ± 2.21 | 25.58 ± 2.75 | 0.071 |
